ROCKVILLE, Md., Nov. 5, 2020 /PRNewswire/ -- REGENXBIO Inc.
(Nasdaq: RGNX), a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy based on its proprietary NAV® Technology
Platform, today announced it will present at the following November
investor conferences, which will each be held in a virtual meeting
format:
29th Annual Credit Suisse Virtual Healthcare
Conference
Date: Thursday,
November 12, 2020
Presentation: Thursday, November 12, 2020 at
8:45 a.m. ET
Barclays Gene Editing & Gene Therapy
Summit
Date: Monday, November 16, 2020
Presentation: Monday, November 16,
2020 at 2:00 p.m. ET
A live webcast of each presentation can be accessed in the
Investors section of REGENXBIO's website
at www.regenxbio.com. An archived replay of each
webcast will be available in the Investors section
of REGENXBIO's website for approximately 30 days
following the presentation.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates in
multiple therapeutic areas.
Contacts:
Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
Eleanor Barisser, 212-600-1902
eleanor@argotpartners.com
Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-present-at-upcoming-investor-conferences-301167441.html
SOURCE REGENXBIO Inc.